Tarallo, Antonietta (2015) Analysis of microRNAs as novel biomarkers in Lysosomal Storage Diseases. [Tesi di dottorato]

[img]
Preview
Text
Tarallo_Antonietta_27.pdf

Download (7MB) | Preview
[error in script] [error in script]
Item Type: Tesi di dottorato
Lingua: English
Title: Analysis of microRNAs as novel biomarkers in Lysosomal Storage Diseases
Creators:
CreatorsEmail
Tarallo, Antoniettatarallo@tigem.it
Date: 31 March 2015
Number of Pages: 77
Institution: Università degli Studi di Napoli Federico II
Department: Scienze Mediche Traslazionali
Scuola di dottorato: Medicina clinica e sperimentale
Dottorato: Riproduzione, sviluppo ed accrescimento dell'uomo
Ciclo di dottorato: 27
Coordinatore del Corso di dottorato:
nomeemail
Pignata, ClaudioUNSPECIFIED
Tutor:
nomeemail
Parenti, GiancarloUNSPECIFIED
Date: 31 March 2015
Number of Pages: 77
Uncontrolled Keywords: microRNAs, pompe disease, fabry disease
Settori scientifico-disciplinari del MIUR: Area 05 - Scienze biologiche > BIO/11 - Biologia molecolare
Area 06 - Scienze mediche > MED/03 - Genetica medica
Area 06 - Scienze mediche > MED/33 - Malattie apparato locomotore
Date Deposited: 09 Apr 2015 08:51
Last Modified: 23 Apr 2016 01:00
URI: http://www.fedoa.unina.it/id/eprint/10448
DOI: 10.6092/UNINA/FEDOA/10448

Abstract

Lysosomal storage disease (LSDs), including Pompe disease (PD) and Fabry disease (FD), represent a group of invalidating pathologies with a strong impact on patients' life expectancy. While remarkable progress in treatment has been made in recent years, the molecular mechanisms responsible for the phenotypic manifestations of these diseases and the key regulators of the functional pathways involved are still to be clarified. Given the increasing relevance conferred to small RNA molecules in human disease, also including neuromuscular disorders, we have studied the possible role of miRNA deregulation in PD and in FD. To globally characterize "disease-specific" miRNA expression profiles, we firsty applied a Next Generation Sequencing (NGS) approach, a new generation technology, quantitative and highly sensitive and more reliable if compared to hybridization-based methods. Identification of specific differentially espressed miRNAs (DE-miRNAs) in plasma and tissues/organs that are primary targets of disease in these LSDs may be exploited to develop novel therapeutic approaches and monitor disease progression. The analysis of miRNAs in these PD and FD represents a way to address some of the unmet medical needs: - Availability of markers of disease progression; - Markers of ERT efficacy; - Optimization of costs of therapies (ERT is highly expensive: 300.000-600.000 eu/year for a single patient); - Possible identification of novel therapeutic targets.

Actions (login required)

View Item View Item